益佰制药(600594.SH)：收到贵州省药品监督管理局《暂停生产/销售解除通知书》

Core Viewpoint - Yibai Pharmaceutical (600594.SH) has temporarily suspended the production and sales of its children's cough syrup due to safety concerns, but has since resolved the issues and resumed operations, with minimal impact expected on overall performance [1] Financial Performance - Revenue from children's cough syrup for the years 2021, 2022, 2023, and 2024 was 3.42 million, 4.32 million, 8.38 million, and 1.51 million respectively, accounting for 0.10%, 0.16%, 0.30%, and 0.07% of the company's total consolidated revenue [1]